Despite concerted efforts at investigating and disseminating the health risks of tobacco dependence, millions of Americans continue to smoke chronically. Drug abusers have twice the smoking rate of the general population and suffer increasingly costly quality of life and health consequences. For example, more than 80% of opioid dependent individuals on buprenorphine maintenance therapy smoke cigarettes. Recent research suggests that cigarette smoking adversely affects brain morphology, blood flow, biochemistry, and cognition. These smoking-related brain abnormalities resemble those observed in chronic drug use and involve major components of the reward circuit, implicated in the initiation and maintenance of all forms of addiction. Tobacco dependence is also related to higher levels of non-nicotinic drug use after drug abuse treatment. The impact of combined opioid and tobacco dependence on neurobiology and behavior has not been evaluated systematically, and its relations to high smoking relapse rates in this population are poorly understood. Recent research implicates abnormalities in the reward circuitry as major contributor to relapse in all drug use, but corresponding evidence from opioid users in tobacco dependence treatment is lacking. The main purpose of this component is to a) obtain magnetic resonance-derived and neurocognitive measures of the integrity of frontal-subcortical brain circuits in opioid dependent individuals on buprenorphine replacement therapy before their extended, innovative tobacco dependence treatment, b) determine if these measures diffenentiate successful and unsuccessful quitters, and c) determine their ability to pnedlct obacco dependence treatment response at 3, 6, 12, and 18 months after treatment randomization. Exploratory genetic studies will address the influence of select single nucleotide polymorphisms on the main neurobiological and treatment outcome measures and the impact of these polymorphisms on quit rates. The overarching purpose of this research is to enable - within the existing framework of the Center - the development of a unique collaboration among two productive research teams at UCSF that both have aimed for many years to help reduce the overall impact of drug abuse on society. This multidisciplinary component, performed as part of a larger clinical trial of extended and innovative tobacco dependence treatment, is expected to increase our understanding of the extent to which neurobiological and cognitive deficiencies as well as specific genotypes contribute to an individual's ability to maintain long-term tobacco abstinence.

Public Health Relevance

Our experience in quantitative measurements of neurobiological and cognitive consequences of drug abuse supports the Center's mission to develop more efficacious tobacco dependence treatment for difficult to treat populations and to focus sparse treatment resources in long-term follow-up on those with more vulnerable phenotypes and genotypes. The proposal will inform on functionally and behaviorally relevant brain dysfunction in drug abuse in general. It complements other research proposed by this Center and provides useful information for public education, health policy, and prediction of treatment outcome.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009253-18
Application #
8376910
Study Section
Special Emphasis Panel (ZDA1-EXL-T)
Project Start
2012-06-01
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
18
Fiscal Year
2012
Total Cost
$558,759
Indirect Cost
$28,405
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Weisner, Constance M; Chi, Felicia W; Lu, Yun et al. (2016) Examination of the Effects of an Intervention Aiming to Link Patients Receiving Addiction Treatment With Health Care: The LINKAGE Clinical Trial. JAMA Psychiatry 73:804-14
Guydish, Joseph; Masson, Carmen; Flentje, Annesa et al. (2016) Scientific writing seminar for early-stage investigators in substance abuse research. Subst Abus 37:238-41
Trager, Evan; Khalili, Mandana; Masson, Carmen L et al. (2016) Hepatitis C Screening Rate Among Underserved Adults With Serious Mental Illness Receiving Care in California Community Mental Health Centers. Am J Public Health 106:740-2
Schuck, Rachel K; Dahl, Audun; Hall, Sharon M et al. (2016) Smokers with serious mental illness and requests for nicotine replacement therapy post-hospitalisation. Tob Control 25:27-32
Guydish, Joseph; Gruber, Valerie A; Le, Thao et al. (2016) A Pilot Study of a Readiness Group to Increase Initiation of Smoking Cessation Services among Women in Residential Addiction Treatment. J Subst Abuse Treat 63:39-45
Guydish, Joseph; Tajima, Barbara; Pramod, Sowmya et al. (2016) Use of multiple tobacco products in a national sample of persons enrolled in addiction treatment. Drug Alcohol Depend 166:93-9
Kalapatapu, Raj K; Delucchi, Kevin L; Wang, Sophia et al. (2016) Substance use history in behavioral-variant frontotemporal dementia versus primary progressive aphasia. J Addict Dis 35:36-41
Barnett, Paul G; Jeffers, Abra; Smith, Mark W et al. (2016) Cost-Effectiveness of Integrating Tobacco Cessation Into Post-Traumatic Stress Disorder Treatment. Nicotine Tob Res 18:267-74
Pagano, Anna; Tajima, Barbara; Guydish, Joseph (2016) Barriers and Facilitators to Tobacco Cessation in a Nationwide Sample of Addiction Treatment Programs. J Subst Abuse Treat 67:22-9
Campbell, Barbara K; Le, Thao; Andrews, K Blakely et al. (2016) Smoking among patients in substance use disorders treatment: associations with tobacco advertising, anti-tobacco messages, and perceived health risks. Am J Drug Alcohol Abuse 42:649-656

Showing the most recent 10 out of 311 publications